Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | P2RX3 | P56373 | 5/20 | 0.36 |
| ▸ | BCL6 | P41182 | 6/20 | 0.35 |
| ▸ | NCOR2 | Q9Y618 | 4/20 | 0.35 |
| ▸ | SCARB1 | Q8WTV0 | 1/20 | 0.35 |
| ▸ | MELK | Q14680 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20284380 | 0.87 | MEN1 (0.39) | MEN1KMT2AP2RX3BCL6NCOR2 | |
| SCHEMBL21787699 | 0.83 | MEN1 (0.39) | MEN1KMT2AP2RX3SCARB1PKM | |
| SCHEMBL21787543 | 0.80 | ADORA2A (0.43) | KMT2ABCL6MELKTDP1 | |
| SCHEMBL29203214 | 0.79 | TDP1 (0.41) | BCL6NCOR2MELKTDP1 | |
| SCHEMBL21787681 | 0.79 | PARG (0.42) | BCL6NCOR2MELKTDP1PKM | |
| SCHEMBL20267392 | 0.78 | CYP1A2 (0.45) | MEN1KMT2ATDP1 | |
| SCHEMBL29874633 | 0.78 | CYP1A2 (0.45) | MEN1KMT2ATDP1 | |
| SCHEMBL21774724 | 0.77 | ALDH1A1 (0.45) | BCL6NCOR2MELKTDP1 | |
| SCHEMBL30232185 | 0.77 | BRD4 (0.41) | MEN1KMT2ABCL6MELKTDP1 | |
| SCHEMBL29203290 | 0.77 | BRD4 (0.41) | MEN1KMT2ABCL6MELKTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11001570-B2 | 6-amino-quinolinone compounds and derivatives as BCL6 inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2021-05-11 | — | — | US | disclosed |
| EP-3555063-B1 | 6-AMINO-QUINOLINONE COMPOUNDS AND DERIVATIVES AS BCL6 INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2020-09-16 | — | — | EP | disclosed |
| US-20200071297-A1 | NEW 6-AMINO-QUINOLINONE COMPOUNDS AND DERIVATIVES AS BCL6 INHIBITORS | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2020-03-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200071297-A1 | NEW 6-AMINO-QUINOLINONE COMPOUNDS AND DERIVATIVES AS BCL6 INHIBITORS | BCL6, BCL6B, BCOR | MEN1 1802/4885KMT2A 216/4885P2RX3 3519/4885 |
| US-11001570-B2 | 6-amino-quinolinone compounds and derivatives as BCL6 inhibitors | BCL6, BCL6B, BCOR | MEN1 1315/4885KMT2A 229/4885P2RX3 3732/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.